Novo Nordisk Logo

Novo Nordisk

Develops medicines and devices for chronic diseases like diabetes, obesity, and rare disorders.

NOVO | CO

Overview

Corporate Details

ISIN(s):
DK0062498333 (+1 more)
LEI:
549300DAQ1CVT6CXN342
Country:
Denmark
Address:
Novo Alle 1, 2880 Bagsværd
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Novo Nordisk is a global healthcare company that discovers, develops, and manufactures innovative biological medicines and therapeutic devices. With a focus on driving change to defeat serious chronic diseases, the company's primary treatment areas include diabetes, obesity, and rare blood and endocrine disorders. Leveraging over 90 years of innovation, Novo Nordisk provides pharmaceutical products and services to patients worldwide, aiming to make its treatments accessible and improve health outcomes.

Social Media

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Novo Nordisk and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-09-10 07:00
Regulatory News Service
English 11.2 KB
2025-09-10 07:00
Earnings Release
English 151.5 KB
2025-08-19 13:37
Director's Dealing
English 17.4 KB
2025-08-19 13:37
Director's Dealing
English 144.5 KB
2025-08-12 14:25
Director's Dealing
English 144.4 KB
2025-08-12 14:25
Director's Dealing
English 17.4 KB
2025-08-08 15:15
Director's Dealing
English 17.4 KB
2025-08-08 15:15
Director's Dealing
English 144.5 KB
2025-08-07 17:30
Director's Dealing
English 159.1 KB
2025-08-07 17:30
Director's Dealing
English 30.5 KB
2025-08-06 07:30
Earnings Release
English 1.4 MB
2025-08-06 07:30
Earnings Release
English 11.9 KB
2025-07-29 13:35
Board/Management Information
English 12.0 KB
2025-07-29 13:35
Board/Management Information
English 176.8 KB
2025-07-29 13:01
Earnings Release
English 167.4 KB

Automate Your Workflow. Get a real-time feed of all Novo Nordisk filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Novo Nordisk via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Valneva SE Logo
Develops and commercializes vaccines for infectious diseases like chikungunya, Lyme, and Zika.
France VLA
VENTURE LIFE GROUP PLC Logo
Develops, manufactures, and distributes consumer self-care products and medical devices globally.
United Kingdom VLG
Vetoquinol SA Logo
Develops and markets veterinary drugs and products for companion animals and livestock worldwide.
France VETO
Vifor Pharma AG Logo
A global leader in specialty pharmaceuticals for iron deficiency and nephrology.
Switzerland VIFN
Virbac Logo
Develops animal health pharma, vaccines & diagnostics for vets, farmers & pet owners globally.
France FR000
ViroGates A/S Logo
Develops suPAR diagnostic tests for inflammation risk assessment in acute care and longevity.
Denmark VIRO
Vistin Pharma Logo
A leading global producer of Metformin Hydrochloride for the global healthcare market.
Norway VISTN
Vita 34 AG Logo
A cell bank storing umbilical cord stem cells as biological insurance for families' future health.
Germany V3V
Vivoryon Therapeutics N.V. Logo
Developing first-in-class small molecule therapies for age-related and kidney diseases.
Germany VVY
WAKAMOTO PHARMACEUTICAL CO.,LTD. Logo
Develops gastrointestinal and ophthalmic drugs for the health challenges of an aging society.
Japan 4512

Talk to a Data Expert

Have a question? We'll get back to you promptly.